脑室 CARv3-TEAM-E 细胞治疗复发性脑胶质瘤。
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
机构信息
From the Cellular Immunotherapy Program (B.D.C., M.J.F., M.B.L., C.W.M., K.G., M.V.M.) and Krantz Family Center for Cancer Research (M.B.L., K.G., M.V.M.), Mass General Cancer Center, and the Departments of Neurology (E.R.G.), Pathology (C.W.M., K.G.), Neurosurgery (B.D.C., L.B., B.S.C., W.T.C.), and Medicine (M.J.F., M.B.L., M.V.M.), Massachusetts General Hospital and Harvard Medical School, and Connell and O'Reilly Families Cell Manipulation Core Facility, Dana-Farber/Harvard Cancer Center (S.N.) - both in Boston.
出版信息
N Engl J Med. 2024 Apr 11;390(14):1290-1298. doi: 10.1056/NEJMoa2314390. Epub 2024 Mar 13.
In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.).
在这项首次人体、研究者发起的、开放性标签研究中，3 名复发性胶质母细胞瘤患者接受了 CARv3-TEAM-E T 细胞治疗，这些 T 细胞是嵌合抗原受体 (CAR) T 细胞，通过分泌一种 T 细胞结合抗体分子 (TEAM) 而被设计成靶向表皮生长因子受体 (EGFR) 变体 III 肿瘤特异性抗原以及野生型 EGFR 蛋白。CARv3-TEAM-E T 细胞治疗未导致大于 3 级或剂量限制性毒性作用的不良事件。影像学肿瘤消退显著且迅速，在单次脑室内输注后数天内发生，但在 3 名参与者中的 2 名中，反应是短暂的。（由 Gateway for Cancer Research 等资助；INCIPIENT ClinicalTrials.gov 编号，NCT05660369。）
Zotero 插件